What is survodutide? Structure, research and status

Survodutide is an investigational peptide that activates both the glucagon receptor and the GLP-1 receptor, developed by Boehringer Ingelheim under license from Zealand Pharma.

Complete guide10 min read

Key takeaway

Survodutide, code name BI 456906, is a dual glucagon receptor and GLP-1 receptor agonist. In SYNCHRONIZE-1, body weight fell 12.2% and 13.0% over 76 weeks in two survodutide groups, versus 5.4% on placebo. In SYNCHRONIZE-CVOT, it did not increase major cardiovascular events versus placebo. Gastrointestinal events were the most common side effects in the published phase 3 obesity trials.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“Survodutide is not approved by the FDA for any use.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited10 in this article · 10 across 1 article on Survodutide
Related productsIncretin analogs

Survodutide is a 29-amino-acid peptide built on a modified human glucagon sequence, with a fatty acid chain attached to extend its time in circulation. It has been tested in obesity, type 2 diabetes and fatty liver disease. Its first phase 3 obesity trials and a cardiovascular safety trial were published in 2026.

Quick answer: Survodutide is an investigational peptide drug in late-stage trials for obesity and the liver disease MASH. Survodutide is not approved by the FDA for any use. FDA has warned companies that sold survodutide labeled for research purposes directly to consumers. A research label does not make such material an approved medicine.

Vitrapep does not sell survodutide; this page is a reference summary of published research and regulatory information.

What is survodutide and how is it built?

Boehringer Ingelheim scientists described survodutide in 2022 under the code BI 456906. The paper says it was co-invented with Zealand Pharma [2].

The rationale comes from oxyntomodulin, a natural 37-amino-acid gut hormone. Oxyntomodulin weakly activates both the glucagon receptor and the GLP-1 receptor. In human studies cited by the authors, it reduced body weight and food intake and raised energy expenditure [2].

Survodutide has 29 amino acids based on the human glucagon sequence, with changes that balance activity at the two receptors [2]. PubChem lists the sequence as His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys-Trp-Leu-Glu-Ser-Ala, with an amidated end [1].

Three features stand out. Position 2 carries 1-aminocyclobutane-1-carboxylic acid (Ac4c), a non-coded amino acid placed where the enzyme DPP-4 normally cuts [2]. The lysine at position 24 carries a glycine-serine linker and a C18 diacid [1], [2]. That fatty acid binds albumin, which lengthens the peptide's half-life [2].

Table 1

What is survodutide and how is it built

PropertySurvodutide
ClassDual glucagon receptor and GLP-1 receptor agonist; acylated peptide [2]
Length29 amino acids, based on a modified human glucagon sequence [2]
Key modificationsAc4c at position 2; glycine-serine linker with a C18 diacid at position 24; amidated C-terminus [1], [2]
Molecular formulaC192H289N47O61 [1]
Molecular weight4,232 g/mol (PubChem computed value) [1]
IdentifiersCode BI 456906; CAS 2805997-46-8 [1]; FDA UNII 2ALA66NS64
Mean residence time in animals44 hours in mice and 140 hours in dogs [2]
DeveloperBoehringer Ingelheim, licensed from Zealand Pharma [12]
FDA approvalNone; openFDA returned no Drugs@FDA record on November 18, 2026

How does survodutide work?

Survodutide activates two receptors in the glucagon family. The GLP-1 receptor supports glucose-dependent insulin release, slows stomach emptying and signals fullness (see what GLP-1 is). The glucagon receptor acts mainly in the liver (see the glucagon complete guide).

Cell findings. In one cell assay, survodutide was roughly 10-fold less potent than native GLP-1 and glucagon at their receptors [2].

Animal findings. In mice, survodutide reduced body weight more than semaglutide at its maximally effective level. The weight loss came from higher energy expenditure and lower food intake [2]. Liver gene expression, plasma amino acids and FGF-21 changed in ways that signal glucagon receptor activity. Studies in GLP-1 receptor knockout mice supported activity at both receptors [2].

Human findings. In phase 1 studies, survodutide lowered plasma amino acids and glucagon. The investigators read this as evidence of engagement at both receptors [3]. Retatrutide adds a third receptor, GIP, to the same glucagon and GLP-1 pair (see the retatrutide complete guide).

What is survodutide being studied for?

With no approved use, there is no label indication to cite. ClinicalTrials.gov listed 37 survodutide studies on November 18, 2026, in three main areas.

Obesity and overweight. SYNCHRONIZE-1 (NCT06066515), SYNCHRONIZE-2 (NCT06066528) and SYNCHRONIZE-CVOT (NCT06077864) are complete. Newer phase 3 trials include SYNCHRONIZE-HERA in women around menopause (NCT07850050).

Liver disease. MASH is metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation. LIVERAGE (NCT06632444) is recruiting an estimated 1,800 adults with moderate or advanced fibrosis. LIVERAGE-Cirrhosis (NCT06632457) plans about 1,590 adults with compensated cirrhosis.

Boehringer says LIVERAGE first measures MASH resolution and fibrosis improvement at 52 weeks. A second part follows liver-related events or death for about 7 years [12]. LIVERAGE-Cirrhosis runs about four and a half years [12].

Type 2 diabetes and kidney disease. A phase 3 glucose-control trial is recruiting (NCT07754461). ARTIST-CKD, a phase 2 trial on albuminuria in kidney disease, is not yet recruiting (NCT07206290). Vitrapep's guide on how to find a peptide clinical trial explains how to read these records.

What did the key survodutide trials show?

Phase 2 obesity trial (NCT04667377). The trial enrolled 387 adults without diabetes at 43 centers. Weight loss rose with dose level. Only 60.4% completed treatment, 61% on survodutide and 60% on placebo [4].

Phase 2 MASH trial (NCT04771273). Adults had biopsy-confirmed MASH with fibrosis stage F1 to F3. Liver fat fell by at least 30% in 57% to 67% of survodutide groups, versus 14% on placebo. Fibrosis improved by at least one stage in 34% to 36%, versus 22% [5].

SYNCHRONIZE-1. Adults had obesity, or overweight with a related complication, and no diabetes. Mean baseline weight was 108.8 kg. At least 5% weight loss occurred in 72.6% and 71.9% of the two survodutide groups, versus 46.3% on placebo [8].

SYNCHRONIZE-2. Participants had type 2 diabetes, with a mean baseline HbA1c of 7.4% [9].

SYNCHRONIZE-CVOT. This event-driven safety trial ran at 524 sites in 34 countries. Its composite endpoint covered cardiovascular death, nonfatal stroke, nonfatal heart attack, ischemia-related coronary revascularization and heart failure events. The noninferiority margin was a hazard ratio of 1.65 [10].

Table 2

What did the key survodutide trials show

TrialPopulation and sizeDesign and lengthPrimary result
Phase 2 obesity, 2024 [4]386 treated adults with BMI 27 or more, no diabetesDouble-blind, placebo-controlled, four dose levels; 46 weeksWeight fell 6.2% to 14.9% across dose groups vs 2.8% on placebo
Phase 2 MASH, 2024 [5]293 treated adults with MASH and fibrosis F1 to F3Double-blind, placebo-controlled, three dose levels; 48 weeksMASH improved without fibrosis worsening in 47%, 62% and 43% vs 14%
SYNCHRONIZE-1, 2026 [8]725 adults with obesity or overweight, no diabetesDouble-blind, placebo-controlled, two dose levels; 76 weeksWeight fell 12.2% and 13.0% vs 5.4% on placebo
SYNCHRONIZE-2, 2026 [9]752 adults with obesity or overweight and type 2 diabetesDouble-blind, placebo-controlled, two dose levels; 76 weeksWeight fell 8.2% and 9.8% vs 3.9%; HbA1c fell 0.9 and 0.8 points vs 0.2
SYNCHRONIZE-CVOT, 2026 [10]5,507 treated adults with BMI 27 or more and heart disease, kidney disease or risk factorsDouble-blind, placebo-controlled, event-driven; median 22.0 months in studyPrimary events 3.7% vs 4.1%; hazard ratio 0.89 (95% CI, 0.67 to 1.18); noninferior

The phase 3 results use the treatment-regimen estimand. It counts outcomes whether or not participants stopped treatment early [8], [10].

In SYNCHRONIZE-MASLD, 216 adults with obesity and at-risk fatty liver disease were treated for 48 weeks. Liver fat fell by at least 30% in 68.5% on survodutide versus 28.6% on placebo [11]. A 16-week phase 2 trial in 413 adults with type 2 diabetes reported HbA1c falls of up to 1.71 points [6]. An open-label phase 1 study found similar drug exposure in people with cirrhosis and in healthy volunteers [7].

What side effects have survodutide trials reported?

Survodutide has no FDA label, boxed warning or label section 6. All safety data below come from trial publications, mostly funded by Boehringer Ingelheim.

Gastrointestinal events. These were the most common adverse events in SYNCHRONIZE-1 and SYNCHRONIZE-2 [8], [9]. In SYNCHRONIZE-1, they occurred in 80.9% and 89.7% of the survodutide groups, versus 47.9% on placebo. No deaths were reported [8]. In SYNCHRONIZE-2, the figures were 72.8% and 77.7%, versus 38.6% [9]. In the phase 2 MASH trial, nausea occurred in 66% versus 23%, and vomiting in 41% versus 4% [5].

Stopping treatment. SYNCHRONIZE-CVOT gives the largest dataset, shown below. About one in five survodutide participants stopped treatment because of gastrointestinal events [10]. In the phase 2 diabetes trial, most stops for adverse events came within the first 6 weeks [6].

Table 3

What side effects have survodutide trials reported

Event in SYNCHRONIZE-CVOT [10]Survodutide, lower dose (N=1,836)Survodutide, higher dose (N=1,835)Placebo (N=1,836)
Any adverse event93.0%93.1%85.6%
Nausea48.0%49.0%12.1%
Vomiting31.7%34.0%4.8%
Stopped treatment for gastrointestinal events19.3%20.8%1.9%
Serious adverse events22.5%20.8%23.9%
Fatal adverse events0.9%0.9%0.6%

Fatal events were mainly due to cardiac disorders, in 0.3% to 0.4% of each group [10].

Heart rate. In the 16-week diabetes trial, mean heart rate rose 2.3 to 7.3 beats per minute across survodutide groups. It rose 5.9 on semaglutide and 1.67 on placebo [6]. In SYNCHRONIZE-MASLD, the week 52 increase was 3.6 versus 0.8 beats per minute [11]. In an early phase 1 study, 7.5% of one cohort stopped because of a cardiac or vascular adverse event [3].

Other events. SYNCHRONIZE-MASLD found no adjudication-confirmed drug-induced liver injury, acute pancreatitis or thyroid cancer in the survodutide group [11]. Serious adverse events in the phase 2 MASH trial occurred in 8% versus 7% on placebo [5].

What is the regulatory status of survodutide?

Approval. Survodutide is not approved by the FDA for any use. The 2026 SYNCHRONIZE-2 report still describes it as investigational [9]. We found no approval by another regulator in the sources we checked.

Development designations. Boehringer reports that FDA granted Fast Track designation in May 2021 for non-cirrhotic MASH with moderate or advanced fibrosis [12]. In September 2024, FDA added a second designation, meant for serious conditions where early clinical evidence suggests substantial improvement over available treatments [12]. The European Medicines Agency accepted survodutide into its PRIME scheme in November 2023 [12]. These designations can speed review but are not approvals.

Research-labeled products. FDA says it has warned companies that illegally sold unapproved survodutide products. Their labels falsely said "for research purposes" or "not for human consumption," according to FDA. The products were sold directly to consumers for human use with dosing instructions [13]. Vitrapep's summary of FDA's August 2026 warning letters covers letters that name survodutide.

A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

Compounding. FDA's page says retatrutide and cagrilintide cannot be used in compounding but does not address survodutide there [13]. We found no other FDA compounding statement on it.

Sport. The WADA 2026 Prohibited List does not name survodutide. Its S0 class covers pharmacological substances not addressed elsewhere and without current regulatory approval for human therapeutic use, including drugs in clinical development [14]. See Vitrapep's WADA 2026 peptide reference.

What is still unknown about survodutide?

SYNCHRONIZE-CVOT was designed to rule out excess cardiovascular risk, not to show benefit. Its confidence interval includes no effect [10]. Liver outcome results from LIVERAGE and LIVERAGE-Cirrhosis are years away [12]. Among the published trials reviewed here, the only comparison with an approved medicine was an open-label semaglutide arm in one 16-week trial [6].

The cause and meaning of the heart rate rise over longer use is not established in the papers reviewed here. In SYNCHRONIZE-CVOT, only 56.0% to 59.0% of each group stayed on treatment until the end, which complicates long-term safety estimates [10].

Frequently asked questions

Is survodutide a peptide?

Yes. It is a 29-amino-acid acylated peptide with a PubChem molecular weight of about 4,232 g/mol.

Is survodutide FDA-approved?

No. It has no FDA approval for any use. FDA granted development designations for MASH, which are not approvals.

How is survodutide different from retatrutide?

Survodutide activates the glucagon and GLP-1 receptors. Retatrutide also activates the GIP receptor. Neither is FDA-approved.

What side effects were most common in survodutide trials?

Gastrointestinal events, mainly nausea, vomiting and diarrhea. In SYNCHRONIZE-CVOT, about one in five participants on survodutide stopped treatment because of them.

Who developed survodutide?

Boehringer Ingelheim develops it under a license from Zealand Pharma, which co-invented it. Boehringer sponsors and funds the trials.

Is research-grade survodutide the same as the trial drug?

Not necessarily. FDA says research-labeled survodutide sold to consumers is of unknown quality and may be harmful.

What to know now

  • Survodutide is a 29-amino-acid peptide that activates the glucagon and GLP-1 receptors, with a C18 diacid that binds albumin.
  • In SYNCHRONIZE-1, weight fell 12.2% and 13.0% over 76 weeks, versus 5.4% on placebo.
  • SYNCHRONIZE-CVOT showed no increase in major cardiovascular events versus placebo, with frequent gastrointestinal side effects.
  • Survodutide is not FDA-approved, and FDA has warned sellers of research-labeled survodutide.

What we’re watching

  • Biopsy results from part one of LIVERAGE in MASH with moderate or advanced fibrosis.
  • Any regulatory filing for obesity or MASH announced by Boehringer Ingelheim.
  • Results from newer phase 3 trials in type 2 diabetes and in women around menopause.

More for endocrine & metabolism

All 48 compounds for endocrine & metabolism

Sources: National Center for Biotechnology Information 2026; Zimmermann 2022, Molecular Metabolism, 66; Jungnik 2023, Diabetes, Obesity and Metabolism, 25; le Roux 2024, Lancet Diabetes & Endocrinology, 12; Sanyal 2024, New England Journal of Medicine, 391; Blüher 2024, Diabetologia, 67; Lawitz 2024, Journal of Hepatology, 81; le Roux 2026, New England Journal of Medicine, 395; Wharton 2026, New England Journal of Medicine; Bozkurt 2026, Lancet; Kaplan 2026, Nature Medicine, 32; Boehringer Ingelheim 2024; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2025. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 171378821, survodutide. https://pubchem.ncbi.nlm.nih.gov/compound/171378821
  2. Zimmermann, T., Thomas, L., Baader-Pagler, T., et al. (2022). BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism, 66, 101633. https://pubmed.ncbi.nlm.nih.gov/36356832/
  3. Jungnik, A., Arrubla Martinez, J., Plum-Mörschel, L., et al. (2023). Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes, Obesity and Metabolism, 25(4), 1011-1023. https://pubmed.ncbi.nlm.nih.gov/36527386/
  4. le Roux, C. W., Steen, O., Lucas, K. J., et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology, 12(3), 162-173. https://pubmed.ncbi.nlm.nih.gov/38330987/
  5. Sanyal, A. J., Bedossa, P., Fraessdorf, M., et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine, 391(4), 311-319. https://pubmed.ncbi.nlm.nih.gov/38847460/
  6. Blüher, M., Rosenstock, J., Hoefler, J., et al. (2024). Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia, 67(3), 470-482. https://pubmed.ncbi.nlm.nih.gov/38095657/
  7. Lawitz, E. J., Fraessdorf, M., Neff, G. W., et al. (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of Hepatology, 81(5), 837-846. https://pubmed.ncbi.nlm.nih.gov/38857788/
  8. le Roux, C. W., Wharton, S., Startseva, E., et al. (2026). Survodutide once weekly for the treatment of adults with obesity. New England Journal of Medicine, 395(8), 776-787. https://pubmed.ncbi.nlm.nih.gov/42253238/
  9. Wharton, S., le Roux, C. W., Startseva, E., et al. (2026). Survodutide once weekly in adults with obesity and type 2 diabetes. New England Journal of Medicine. Published online October 1, 2026. https://pubmed.ncbi.nlm.nih.gov/42820639/
  10. Bozkurt, B., le Roux, C. W., Wharton, S., et al. (2026). Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. Published online November 9, 2026. https://pubmed.ncbi.nlm.nih.gov/43003106/
  11. Kaplan, L. M., Startseva, E., le Roux, C. W., et al. (2026). Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine, 32(8), 2948-2958. https://pubmed.ncbi.nlm.nih.gov/42252333/
  12. Boehringer Ingelheim. (2024, October 8). Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide [Press release]. https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash
  13. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  14. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf